非小细胞肺癌患者PD-1基因单核苷酸多态性与远期生存的关系
The relationship between PD-1 gene single nucleotide polymorphism and long-term survival in non-small cell lung cancer patients
吴俊沛 1方权 2朱晓丹3
作者信息
- 1. 浙江中医药大学研究生院,杭州 310053;义乌市中心医院呼吸内科,义乌 322000
- 2. 义乌市中心医院放射科,义乌 322000
- 3. 义乌市中心医院呼吸内科,义乌 322000
- 折叠
摘要
目的 探讨非小细胞肺癌(NSCLC)患者程序性细胞死亡1(PD-1)基因单核苷酸多态性与远期生存的关系.方法 选择2020年6月至2022年6月义乌市中心医院收治的80例NSCLC患者,采用聚合酶链式反应限制性片段长度多态性检测患者外周血中PD-1.1(rs36084323)及PD-1.5(rs2227981)位点多态性.随访统计NSCLC患者的无进展生存期(PFS)及总生存期(OS).分析非小细胞肺癌患者PD-1基因型与临床参数的相关性.并采用Cox单因素和多因素分析评估NSCLC患者PFS和OS的影响因素.结果 NSCLC患者PD-1.1位点AA、AG、GG基因型占比分别为30:00％、50.00％、20.00％,PD-1.5 位点 CC、CT、TT 基因型患者占比分别为 55.00％、38.75％、6.25％,差异均无统计学意义(均P＞0.05).PD-1.1基因型与分化程度有关(P＜0.05);PD-1.5基因型与淋巴结转移有关(P＜0.05).PD-1.1位点AA、AG、GG基因型患者中位PFS分别为15.00(95％CI:1.65～28.35)个月、15.00(95％CI:10.53～19.47)个月、11.00(95％CI:5.12～16.88)个月,中位 OS 分别为 30.00(95％CI:23.58～36.42)个月、31.00(95％CI:29.45～32.56)个月、22.00(95％CI:11.56～32.44)个月,三种基因型PFS、OS差异均无统计学意义(均P＞0.05).PD-1.5位点CC、CT+TT基因型患者中位 PFS 分别为 18.00(95％CI:12.47～23.53)个月、10.00(95％CI:6.47～13.53)个月,中位 OS 分别为 32.00(95％CI:29.86～34.14)个月、22.00(95％CI:15.25～28.75)个月,差异均有统计学意义(均P＜0.05).Cox多因素分析结果显示,NSCLC患者临床分期、淋巴结转移、PD-1.5位点基因型是PFS的独立影响因素(均P＜0.05);年龄、临床分期、淋巴结转移、PD-1.5位点基因型是OS的独立影响因素(均P＜0.05).结论 PD-1.5位点多态性与NSCLC患者远期生存相关,为NSCLC机制研究及靶向治疗提供了新的研究思路.
Abstract
Objective To explore the relationship between single nucleotide polymorphism of programmed cell death 1(PD-1)gene and long-term survival in non-small cell lung cancer(NSCLC)patients.Methods Eighty NSCLC patients admitted to the Yiwu Central Hospital from June 2020 to June 2022 were selected.Polymerase chain reaction restriction fragment length polymorphism was used to detect the PD-1.1(rs36084323)and PD-1.5(rs2227981)polymorphisms in the peripheral blood of the patients.Follow-up statistics were conducted on the progression free survival(PFS)and overall survival(OS)of NSCLC patients.We also analyzed the correlation between PD-1 genotype and clinical parameters in non-small cell lung cancer patients.And Cox univariate and multivariate analyses were used to evaluate the influencing factors of PFS and OS in NSCLC patients.Results The proportion of PD-1.1 AA,AG,and GG genotypes in NSCLC patients was 30.00％,50.00％,and 20.00％,respectively,while the proportion of PD-1.5 CC,CT,and TT genotypes in NSCLC patients was 55.00％,38.75％,and 6.25％,respectively.The differences were not statistically significant(all P＞0.05).PD-1.1 genotype was correlated with differentiation degree(P＜0.05);PD-1.5 genotype was associated with lymph node metastasis(P＜0.05).The median PFS of patients with PD-1.1 genotype AA,AG,and GG were 15.00(95％CI:1.65-28.35)months,15.00(95％CI:10.53-19.47)months,and 11.00(95％CI:5.12-16.88)months,respectively.The median OS was 30.00(95％CI:23.58-36.42)months,31.00(95％CI:29.45-32.56)months,and 22.00(95％CI:11.56-32.44)months,respectively.There was no statistically significant difference in PFS and OS among the three genotypes(all P＞0.05).The median PFS of patients with PD-1.5 locus CC and CT+TT genotypes were 18.00(95％CI:12.47-23.53)months and 10.00(95％CI:6.47-13.53)months,respectively.The median OS was 32.00(95％CI:29.86-34.14)months and 22.00(95％CI:15.25-28.75)months,respectively,and the differences were statistically significant(all P＜0.05).The Cox multivariate analysis results showed that clinical stage,lymph node metastasis,and PD-1.5 locus genotype were independent influencing factors for PFS in NSCLC patients(all P＜0.05);Age,clinical stage,lymph node metastasis,and PD-1.5 locus genotype are independent influencing factors for OS(all P＜0.05).Conclusions The PD-1.5 locus polymorphism is associated with long-term survival in NSCLC patients,providing new research ideas for the mechanism research and targeted therapy of NSCLC.
关键词
癌,非小细胞肺/程序性细胞死亡受体1/多态性,单核苷酸/无进展生存期Key words
Carcinoma,non-small-cell lung/Programmed cell death 1 receptor/Polymorphism,single nucleotide/Progression-free survival引用本文复制引用
出版年
2024
NETL
NSTL
万方数据